The early peptide tissue-repair literature was dominated by BPC-157, partly because it was the first compound in its class to attract sustained preclinical investigation and partly because of its remarkable stability profile. But the broader field has expanded substantially. Several mechanistically distinct classes of regenerative peptides are now under active investigation, each with characteristic phenotypes and limitations.
The thymosin family — anchored by Thymosin Beta-4 (Tβ4) and its fragment TB-500 — operates through actin-cytoskeleton modulation, facilitating the cell migration that is a prerequisite for early wound infiltration. Tβ4 has a documented role in cardiac regeneration following infarction, where it appears to promote progenitor-cell recruitment alongside its anti-apoptotic effects.
The copper peptide family, principally represented by GHK-Cu, operates through broad transcriptional reprogramming. Documented gene-expression changes span more than 4,000 transcripts and include up-regulation of antioxidant defenses, anti-inflammatory programs, and matrix-remodeling enzymes. The peptide-mineral complex is required for full activity; the apo-peptide is substantially less active.
The KPV tripeptide (the C-terminal of α-MSH) targets inflammatory transcription directly, attenuating NF-κB signaling without the broader melanocortin-receptor effects of the parent hormone. This makes it of interest in inflammation-dominated repair contexts (inflammatory bowel disease, atopic dermatitis, mucositis) where the goal is suppression of pathological inflammation rather than amplification of regenerative signaling.
Engineered growth-factor mimetics — small peptides designed to engage specific receptor tyrosine kinases — represent the most translationally ambitious end of the field. The unifying challenge across all these approaches is the same as for BPC-157 itself: how to translate consistent preclinical findings into rigorously controlled clinical trials.